Compare ProShares Ultra Gold ETF (UGL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra Gold ETF trades at $45.73, while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| UGL | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $85.62 | $164.28 |
52-Week Low | $33.59 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL (ProShares Ultra Gold) trades at $43.39, down 0.41% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF lacks fundamental financial ratios like P/E or P/B as it tracks gold futures. Recent news highlights gold's volatility amid Middle East tensions and interest rate uncertainty, with some analysts seeing a potential rebound from oversold conditions.
Outlook remains mixed: gold's safe-haven demand supports upside, but higher interest rates pose headwinds. Risks include Fed policy shifts and geopolitical developments. Institutional sentiment is cautious, with technicals favoring short-term bearishness despite some oversold signals suggesting potential stabilization.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
